Cerebral Sinus Thrombosis in a Trauma Patient after Recombinant Activated Factor VII Infusion

SEVERAL investigators have reported the astonishing effect of recombinant activated factor VII (rFVIIa) in trauma patients with diffuse bleeding. Currently, rFVIIa is approved for the treatment of patients with hemophilia with inhibitors to factors VIII and IX. Conditions with increased thromboembolic risk, including trauma, extensive tissue damage, sepsis, arteriosclerosis, and disseminated intravascular coagulation, may be considered contraindications for the drug. Thrombotic complications in trauma patients are rarely observed. To our knowledge, this is the first report of a patient who experienced a cerebral sinus thrombosis in the posttraumatic period after rFVIIa administration.